Developing in vivo CAR T-cell therapies requires reliable approaches for transient, controlled CAR expression and targeted mRNA delivery to immune cells. This webinar will examine the transformative ...

Newcells offers a range of physiologically-relevant and functionally-validated iPSC and primary-cell models to support drug developers de-risk pre-clinical decision-making and improve clinical ...

DURHAM, N.C.--(BUSINESS WIRE)--Advanced Medicine Partners, an organization that delivers process development, manufacturing, analytical development and testing for advanced therapy products, today ...

Cambrex, a CDMO, signed an agreement with Eli Lilly to deliver accelerated access to clinical development capabilities for Lilly’s biotech collaborators. The company will partner with Lilly ...

The sheer growth of small biotechs and mid‑sized pharma companies entering the field has reshaped expectations of Contract Development and Manufacturing Organisations (CDMOs).

The advent and proliferation of targeted modalities represent an evolutionary leap forward in drug development. By binding ...

DUBLIN, Ireland, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including ...

Serán Bioscience, LLC,  in collaboration with leading developer and design-builder Mortenson, hosted a topping-out ceremony ...

VILNIUS, LT / ACCESS Newswire / July 29, 2025 / Diorasis Therapeutics (“DTx”), a preclinical-stage biotechnology company developing gene therapies for ophthalmic diseases, has entered into a strategic ...

As biologics programs progress toward commercialization, late-stage development introduces distinct challenges—from scaling processes efficiently to ensuring regulatory readiness and maintaining cost ...